Elizabeth Faust

Elizabeth Faust, Ph.D. has served as a member of our board of directors since June 2022. Dr. Faust is the principal and owner of Faust Consulting LLC where she works with start-up and bio-pharmaceutical companies. Most recently, she served as the Executive Vice President of Medical Affairs at Tricida Inc where she built and led Medical Affairs and oversaw the Safety and Pharmacovigilance functions. Previously, Dr. Faust was the Vice President of Medical Affairs at Kite Pharma where she built and led the Medical Affairs function supporting the launch of Yescarta, the first cell therapy for lymphoma before transitioning her responsibilities to Gilead after the acquisition. Before that, she was the Vice President of Medical Affairs at Pharmacyclics where she built and led Medical Affairs through 4 launches for Imbruvica and the Abbvie acquisition. Dr. Faust has also served in senior roles in Medical Affairs at Celgene and Gloucester Pharmaceuticals (acquired by Celgene). She was at Amgen for 12 years in the Research, Development and Medical Affairs departments. Dr. Faust has over 26 years in the bio-pharmaceutical industry. She was a key contributor to the launch of 9 new molecular entities (small molecules, biologics and cell therapy) and 4 successful BLA/NDA submissions. Dr. Faust holds a B.S. in Microbiology from Auburn University and a Ph.D. in Microbiology and Molecular Genetics from UCLA. Dr. Faust is qualified to serve on the board of directors due to her extensive experience in drug development and her background as a senior executive in biotechnology and pharmaceutical companies.